ReviewRisk management and healthcare policy2021
The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges.
Review in Risk management and healthcare policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 57 citations in OpenAlex.
- The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.Current oncology (Toronto, Ont.) · 2025Review
- Ritual to relief: ethical frontiers in repurposing psychoactive substances.CNS spectrums · 2025Review
- Review
- The Psych Behind Psychedelics: Exploring Hallucinogen Use as a Marker for Untreated Mental Health Disorders.Health psychology research · 2025Article
- Psychedelic Regulation Beyond the Controlled Substances Act: A Three-Dimensional Framework for Characterizing Policy Options.The American journal of psychiatry · 2025Article
- Substance Use and Mental Health in Emerging Adult University Students Before, During, and After the COVID-19 Pandemic in Mexico: A Comparative Study.Diseases (Basel, Switzerland) · 2024Article
- Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.Scientific reports · 2024Article
- Review
- The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.Addiction biology · 2024Review
- Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Review
- Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic.Scientific reports · 2023Article
- Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the "God Molecule".Pharmaceuticals (Basel, Switzerland) · 2023Review
- Hallucinations and Hallucinogens: Psychopathology or Wisdom?Culture, medicine and psychiatry · 2023Article
- Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies.Molecular psychiatry · 2023Review
- Psychedelics and neonihilism: connectedness in a meaningless world.Frontiers in psychology · 2023Review
- Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant.Biomolecules · 2022Review
- Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.Journal of palliative medicine · 2022Article
- Classic Psychedelics and Human-Animal Relations.International journal of environmental research and public health · 2022Article
- Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.Psychopharmacology · 2022Review
- New Paradigms of Old Psychedelics in Schizophrenia.Pharmaceuticals (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychedelics or serotonergic hallucinogens are a group of substances that share the agonism of serotonergic 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.